NexImmune to Present at the 2021 Barclays Global Healthcare Conference
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company, announced that CEO Scott Carmer will present a company overview at the virtual 2021 Barclays Global Healthcare Conference on March 11, 2021, at 10:55 a.m. Eastern time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company, announced that CEO Scott Carmer will present a company overview at the virtual 2021 Barclays Global Healthcare Conference on March 11, 2021, at 10:55 a.m. Eastern time.
The presentation will be available via live webcast, and a replay will be accessible on the NexImmune website post-event. The company focuses on developing innovative immunotherapy designed to direct antigen-specific T cells for a targeted immune response, promoting a potent and durable reaction mimicking natural biology.
Details
News Market Reaction – NEXI
The recorded move for NEXI in the trading session of this news was +2.38%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will present a company overview at the virtual 2021 Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 10:55 a.m. Eastern time.
The presentation will be accessible via live webcast by visiting https://ir.neximmune.com/investors/events-and-presentations. A replay will be available on the NexImmune website following the presentation.
About NexImmune
NexImmune, based in Gaithersburg, Maryland, is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells to generate a specific, potent and durable immune response that mimics natural biology. For more information, visit www.neximmune.com.
Contacts
Investors:
Chad Rubin
Solebury Trout
646-378-2947
crubin@soleburytrout.com
Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312-961-2502
mikebeyer@sambrown.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.